IDEAYA Biosciences Stock Surges 27% on Trial

IDEAYA Biosciences shares jumped 27% on Monday after its Phase 2/3 OptimUM‑02 trial met primary endpoint in metastatic uveal melanoma.
Median progression‑free survival improved to 6.9 months versus 3.1 months, hazard ratio 0.42 (95% CI 0.30‑0.59).
Overall response rate was 37.1% for darovasertib + crizotinib versus 5.8% for investigator‑choice therapy, with a 58% risk reduction.
IDEAYA will file an FDA New Drug Application in H2 2026 and present full data at a major 2026 medical conference.